We are live on ! Find out more
CCA

Cravens & Co Advisors Portfolio holdings

AUM $154M
1-Year Est. Return 17.67%
This Fund
S&P 500
This Quarter Est. Return
+4.53%
1 Year Est. Return
+17.67%
3 Year Est. Return
+52.1%
5 Year Est. Return
10 Year Est. Return
AUM
$146M
AUM Growth
+$12.5M
Cap. Flow
+$6.53M
Cap. Flow %
4.46%
Top 10 Hldgs %
66.14%
Holding
59
New
4
Increased
22
Reduced
26
Closed
1

Sector Composition

Rank Sector Weight
1 Financials 9.21%
2 Technology 6.58%
3 Healthcare 4.79%
4 Communication Services 3.75%
5 Consumer Discretionary 3.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IP icon
51
International Paper
IP
$22.3B
$290K 0.2%
+6,243
New +$305K
VOE icon
52
Vanguard Mid-Cap Value ETF
VOE
$23.7B
$272K 0.19%
1,560
BMY icon
53
Bristol-Myers Squibb
BMY
$127B
$249K 0.17%
5,514
+122
+2% +$5.7K
VALE icon
54
Vale
VALE
$62.9B
$220K 0.15%
20,291
-239
-1% -$2.44K
CCI icon
55
Crown Castle
CCI
$32.7B
$215K 0.15%
2,230
-27
-1% -$2.73K
CGGO icon
56
Capital Group Global Growth Equity ETF
CGGO
$11.2B
$214K 0.15%
6,260
-11
-0.2% -$361
MSOS icon
57
AdvisorShares Pure US Cannabis ETF
MSOS
$864M
$81.3K 0.06%
16,968
PSEC icon
58
Prospect Capital
PSEC
$1.06B
$55K 0.04%
20,000
MO icon
59
Altria Group
MO
$122B
-7,574
Closed -$444K

Similar funds

Cravens & Co Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Cravens & Co Advisors held 59 positions worth $146M, up 9.3% from $134M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Cravens & Co Advisors deployed $6.53M of net new capital in Q3 2025, opening 4 new positions and adding to 22 existing holdings. Its largest new stake was PGIM Ultra Short Bond ETF: 150,697 shares worth $7.51M.

By sector, the portfolio is most concentrated in Financials at 9.2% of assets, down from 11% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was SmartFinancial, an estimated $2.12M trimmed.

  • Cravens & Co Advisors's largest Q3 2025 buy was PGIM Ultra Short Bond ETF: 150,697 shares worth $7.51M.
  • Cravens & Co Advisors added most to Vertex Pharmaceuticals in Q3 2025, an estimated $433K increase.
  • Cravens & Co Advisors's biggest Q3 2025 reduction was SmartFinancial, cutting an estimated $2.12M.
  • Cravens & Co Advisors fully exited Altria Group in Q3 2025, selling an estimated $444K.
  • Cravens & Co Advisors's ten largest holdings make up 66% of its $146M portfolio in Q3 2025.
  • Cravens & Co Advisors opened 4 new positions and closed 1 in Q3 2025.
  • Cravens & Co Advisors's portfolio value rose 9.3% quarter-over-quarter to $146M.

Based on Cravens & Co Advisors's 13F filing for Q3 2025, filed 29 Oct 2025.